Mirum Pharmaceuticals Inc. (Mirum (MIRM)) shares are having a strong Monday, up over 13% after the company announced that its experimental drug volixibat hit its primary endpoint in a Phase 2b study. The drug is being developed for cholestatic pruritus—basically, severe itching caused by liver disease—in patients with primary sclerosing cholangitis, or PSC.
PSC is a chronic, progressive, and rare liver disease where the bile ducts become inflamed, scarred, and narrowed. It's not a fun condition, and there aren't a ton of great treatment options, so any progress is a big deal for patients and investors alike.
Volixibat Shows Statistically Significant Itch Reduction
The VISTAS Phase 2b study showed a statistically significant reduction in cholestatic pruritus, with patients experiencing a 2.72-point improvement from baseline and a 1.64-point placebo-adjusted reduction. Those numbers might not sound huge, but for people suffering from constant itching, even a modest improvement can be life-changing.
Mirum has scheduled a pre-New Drug Application (NDA) meeting with the FDA for summer 2026, and full results will be presented at the EASL International Liver Congress on May 30. That's a key milestone—getting the FDA's feedback before filing for approval is a smart move that can save time and money.
AZURE-1 Study Adds Momentum With Strong Antiviral Data
Last week, Mirum also reported positive results from the Phase 2b portion of its AZURE-1 study of brelovitug for chronic hepatitis delta virus (HDV). HDV is a nasty co-infection that makes hepatitis B even worse, and there aren't many effective treatments.
At Week 24, brelovitug showed impressive antiviral activity. In the 300 mg once-weekly dose group, 100% of patients achieved a virologic response. In the 900 mg once-every-four-weeks group, 75% responded. In the delayed treatment arm—the control group—zero percent responded. That's a striking difference.
The primary composite endpoint—virologic response plus normalization of liver enzyme ALT—was achieved in 45% of patients on the weekly dose and 35% on the monthly dose, compared to 0% in the control group. These data suggest brelovitug could be a real option for HDV patients.
MIRM Technical Outlook: Trend, Support And Resistance
Mirum is currently trading within its 52-week range, which has seen a high of $109.28 and a low of $40.00. The stock is trading 8.4% above its 20-day simple moving average (SMA) and 9.1% above its 100-day SMA, suggesting a bullish short-term trend.
The 50-day SMA is at $93.83, and the stock is trading 5.5% above that level, reinforcing the positive momentum. The relative strength index (RSI) is at 53.58, which is neutral—meaning the stock isn't overbought or oversold, so there's room to run either way.
- Key Resistance: $99.50 — This level may act as a barrier for upward movement.
- Key Support: $84.50 — This level could provide buying interest if tested.
Over the past 12 months, Mirum has delivered a stunning 119.71% return, reflecting strong investor interest and long-term growth potential. That kind of performance tends to attract attention, and Monday's move to a new 52-week high only adds to the story.
MIRM Price Action: Mirum Pharmaceuticals shares were up 13.27% at $109.34 at the time of publication on Monday, hitting a new 52-week high, according to market data.
